US Stock MarketDetailed Quotes
SNDX Syndax Pharmaceuticals
- 16.090
- +0.490+3.14%
Close Nov 22 16:00 ET
- 16.250
- +0.160+0.99%
Post 18:41 ET
1.37BMarket Cap-4420P/E (TTM)
16.260High15.410Low1.47MVolume15.670Open15.600Pre Close23.36MTurnover1.85%Turnover RatioLossP/E (Static)85.36MShares25.34052wk High3.75P/B1.27BFloat Cap15.00052wk Low--Dividend TTM79.18MShs Float29.860Historical High--Div YieldTTM5.45%Amplitude3.390Historical Low15.946Avg Price1Lot Size
Syndax Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -39.57%-62.32M | -102.55%-71.65M | -112.98%-83.55M | -20.14%-160.6M | -80.61%-41.35M | -56.44%-44.65M | 12.24%-35.37M | 6.45%-39.23M | -558.88%-133.68M | -122.73%-22.89M |
| Net income from continuing operations | -64.48%-84.13M | -52.56%-68.06M | -76.04%-72.4M | -40.19%-209.36M | -84.91%-72.47M | -44.47%-51.15M | -18.75%-44.62M | -10.65%-41.13M | -699.13%-149.34M | -140.74%-39.19M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 51.93%-187K | --0 |
| Depreciation and amortization | -33.33%2K | 0.00%3K | 0.00%3K | -63.64%12K | 0.00%3K | -62.50%3K | -72.73%3K | -72.73%3K | -23.26%33K | -70.00%3K |
| Other non cash items | 24.47%295K | 62.42%242K | 121.82%244K | -51.51%739K | 116.96%243K | -73.43%237K | -42.25%149K | -58.02%110K | 714.97%1.52M | 123.73%112K |
| Change In working capital | 693.90%12.63M | -312.31%-10.07M | -3,289.51%-16.47M | 1,823.91%31.86M | 86.20%26.01M | -39.60%1.59M | 171.10%4.75M | 94.13%-486K | 117.26%1.66M | 1,006.89%13.97M |
| -Change in receivables | 317.44%8.48M | -292.54%-7.64M | ---6.07M | ---- | ---- | -145.53%-3.9M | 157.98%3.97M | --0 | ---- | ---- |
| -Change in prepaid assets | -185.48%-10.68M | 180.49%1.96M | -198.45%-2.85M | 122.75%676K | -15.84%3.96M | -36.30%-3.74M | -169.69%-2.44M | 134.39%2.9M | -113.20%-2.97M | 6,006.49%4.7M |
| -Change in payables and accrued expense | 55.66%14.37M | -177.08%-4.09M | -43.79%-7.86M | 152.75%20.48M | 39.17%11.42M | 389.80%9.23M | 259.02%5.3M | -185.18%-5.47M | 64.34%8.1M | 592.15%8.2M |
| -Change in other working capital | ---- | ---- | -84.87%315K | 408.18%10.71M | ---- | ---- | ---- | --2.08M | 73.55%-3.47M | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -39.57%-62.32M | -102.55%-71.65M | -112.98%-83.55M | -20.14%-160.6M | -80.61%-41.35M | -56.44%-44.65M | 12.24%-35.37M | 6.45%-39.23M | -558.88%-133.68M | -122.73%-22.89M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 116.70%86.85M | -16.45%61.75M | -599.12%-99.4M | 163.17%117.61M | 88.16%-16.29M | 689.97%40.08M | 247.97%73.91M | 143.40%19.92M | -355.53%-186.19M | -129.55%-137.63M |
| Net PPE purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 274.42%225K | --0 |
| Net investment purchase and sale | 116.70%86.85M | -16.45%61.75M | -599.12%-99.4M | 163.09%117.61M | 88.16%-16.29M | 671.06%40.08M | 247.97%73.91M | 143.40%19.92M | -357.52%-186.41M | -130.04%-137.63M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 116.70%86.85M | -16.45%61.75M | -599.12%-99.4M | 163.17%117.61M | 88.16%-16.29M | 689.97%40.08M | 247.97%73.91M | 143.40%19.92M | -355.53%-186.19M | -129.55%-137.63M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 67.37%3.1M | -48.94%676K | -12.37%2.17M | 53.34%264.13M | 58.09%258.48M | 113.69%1.85M | -93.90%1.32M | 344.17%2.47M | 45.41%172.25M | 48.94%163.5M |
| Net issuance payments of debt | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---21M | --2K |
| Net common stock issuance | ---- | ---- | ---- | 42.29%258.09M | ---- | ---- | ---- | ---- | 110.10%181.39M | 99.45%161.96M |
| Proceeds from stock option exercised by employees | 67.37%3.1M | -48.94%676K | -12.37%2.17M | -49.09%6.04M | -74.69%389K | -75.23%1.85M | -42.26%1.32M | 344.17%2.47M | -62.41%11.86M | -94.51%1.54M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 67.37%3.1M | -48.94%676K | -12.37%2.17M | 53.34%264.13M | 58.09%258.48M | 113.69%1.85M | -93.90%1.32M | 344.17%2.47M | 45.41%172.25M | 48.94%163.5M |
| Net cash flow | ||||||||||
| Beginning cash position | 8.33%105.61M | 99.25%114.83M | 296.95%295.61M | -66.47%74.47M | 32.56%94.77M | -19.00%97.49M | -69.49%57.63M | -66.47%74.47M | 92.51%222.08M | -0.08%71.49M |
| Current changes in cash | 1,113.69%27.62M | -123.13%-9.22M | -973.57%-180.78M | 249.81%221.14M | 6,641.99%200.84M | 94.42%-2.73M | 158.16%39.86M | 49.27%-16.84M | -238.31%-147.61M | -98.02%2.98M |
| End cash Position | 40.59%133.24M | 8.33%105.61M | 99.25%114.83M | 296.95%295.61M | 296.95%295.61M | 32.56%94.77M | -19.00%97.49M | -69.49%57.63M | -66.47%74.47M | -66.47%74.47M |
| Free cash flow | -39.57%-62.32M | -102.55%-71.65M | -112.98%-83.55M | -20.14%-160.6M | -80.61%-41.35M | -56.44%-44.65M | 12.24%-35.37M | 6.45%-39.23M | -560.92%-133.68M | -122.76%-22.89M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data